Ryusuke Sakamoto

Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in db/db mice

Takashi Nakamura, Takayo Murase, Mai Nampei et al. · European Journal of Pharmacology · 2016 · 80 citations

Medicine, Pharmacology, Physiology +6

Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study)

Takashi Wada, Tatsuo Hosoya, Daisuke Honda et al. · Clinical and Experimental Nephrology · 2018 · 59 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double‐blind, double‐dummy, active‐controlled, parallel‐group study

Tatsuo Hosoya, Yoshihiro Ogawa, Hiroya Hashimoto et al. · Journal of Clinical Pharmacy and Therapeutics · 2016 · 57 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double‐blind, placebo‐controlled study

Tatsuo Hosoya, Tetsuhiko Sasaki, Hiroya Hashimoto et al. · Journal of Clinical Pharmacy and Therapeutics · 2016 · 43 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Multicenter, Open-Label Study of Long-Term Topiroxostat (FYX-051) Administration in Japanese Hyperuricemic Patients with or Without Gout

Tatsuo Hosoya, Tomohiko Ishikawa, Yoshimi Ogawa et al. · Clinical Drug Investigation · 2018 · 21 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14